2020 OPDP Wrap-up: FDA monitoring drug manufacturers’ use of online communication platforms
By EsqSocial Corporation 26/01/21
In 2020, the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) issued four warning letters and two untitled letters to pharmaceutical companies for promotional materials that allegedly misbranded prescription drug products in violation of the Federal Food, Drug, and Cosmetic Act (FDCA) and the agency’s regulations....
By: Hogan Lovells